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Abstract.
Background: Little is known about the organization of clinical services for Huntington’s disease (HD).
Objective: To describe how health care services are organized and delivered in HD-clinics taking part in or eligible for the
Enroll-HD study.
Methods: In 2014, a 69-item survey was administered to sites taking part in or eligible for the Enroll-HD study.
Results: Of 231 sites surveyed, 121 (52.2%) sites in Europe, North America, Latin America, and Oceania responded. Most
sites in the sample serve large populations, with 61.1% serving more than 1.5 million people, and a further 33% serving
>500,000. Almost all (86.0%) centers see patients from outside their region. The majority of centers (59.7%) follow 50–199
patients, 21.9% care for more than 200. Most centers provide care in all stages of HD, and nearly all review pre-symptomatic
cases. Multidisciplinary case reviews are offered in 54.5% of sites, with outreach clinics offered by 48.1%. Videoconferencing
and telemedicine are used by 23.6%. Separate consultations for caregivers are offered in more than half of the centers. Most
centers (70.4%) report following published guidelines or local care pathways for HD.
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Conclusions: Most centers serve a large population and use a multidisciplinary approach. The survey gives insight into
factors underpinning HD service delivery globally. There is a need for more in-depth studies of clinical practice to understand
how services are organized and how such features may be associated with quality of care.
Keywords: Huntington’s disease, health services, quality of health care
INTRODUCTION
Huntington’s disease (HD) is a neurodegener-
ative genetic disorder with autosomal dominant
inheritance [1], characterized by progressive motor
abnormalities, cognitive impairment and psychiatric
disturbances [1–3]. Clinical features of HD usually
develop during adult life, most commonly between
the ages of 30 to 60 years, and disease duration from
first clinical symptoms through complete care depen-
dency to death is approximately 15–20 years [1].
HD patients in early to middle stages of the dis-
ease may benefit from coordinated multidisciplinary
health care services, including regular follow up, neu-
rological and cognitive assessments, physiotherapy
[4, 5], speech therapy training [6, 7], and occupa-
tional therapy [8]. Patients in advanced stages of the
disease are usually dependent on fulltime personal
care [9]. Family members and caregivers need sup-
port and guidance [10, 11]. Young people who are
at-risk are burdened with difficult family dynamics,
uncertainty around gene status and in many cases
parental caregiving.
At present, there is no curative treatment for HD,
so treatment is aimed at alleviating symptoms, and
maintaining and improving function and quality of
life [1]. There is a high reliance on informal care
in HD [12], and a study from Norway found that
patients and caregivers report significant unmet needs
for health services [13]. There is general agree-
ment that comprehensive and multidisciplinary care
is needed for individuals and families affected by HD
[1, 14–17]. Coordination of services, including med-
ical and clinical services and social and community
resources, is central in multidisciplinary approach.
Standards of care and guidelines for management of
individuals and families affected by HD have been
published with the purpose of being a foundation for
further research and evaluation of care provided [17].
Multidisciplinary care is considered the gold stan-
dard in care delivery in complex chronic disease,
including Huntington’s disease [1]. Refinements in
the organization of care delivery have improved qual-
ity of life and survival for patients with chronic
disease, as demonstrated in cystic fibrosis [18, 19]
and Parkinson’s disease [20, 21]. Studies of out-
comes related to multidisciplinary or integrated care
in Parkinson’s disease revealed mixed results [20,
21], suggesting that some components of multidis-
ciplinary care may be more important than others.
Another study revealed that hospitalization rates for
patient with Parkinson’s disease are lower in patients
seen by neurologists compared to generalists [22].
The introduction of a HD nurse specialist resulted
in decreased hospital admissions by 51%, and hos-
pitalization was more appropriate in those who were
admitted, suggesting that care management services
may be a critical component of service delivery in HD
[23]. Overall, there is a lack of research into how care
delivery influences outcomes in HD. Little is known
about the variability in the organization of HD ser-
vices globally, the sizes of populations served, and
organization of HD-clinics.
Enroll-HD [NCT01574053] is an international,
observational study and research platform that
intends to follow a large cohort of individuals diag-
nosed with and at-risk for HD along with family
controls and relatives who have tested gene-negative
with detailed annual assessments and specimen col-
lection. The study currently includes more than 130
study sites in North America, Europe, Latin America
and Oceania, and has enrolled over 10,000 partic-
ipants as of April 2016. In addtion, study sites in
the European Huntington Disease Network’s REG-
ISTRY study [NCT01590589] are eligible for the
Enroll-HD study. In order to explore structures and
processes underpinning clinical management that
may be relevant for improving the health and wellbe-
ing for those affected by HD, the Care Improvement
Committee (CIC), part of the Enroll-HD governance,
performed a survey to describe how services are orga-
nized and delivered across HD-clinics taking part in
or eligible for the Enroll-HD study.
MATERIALS AND METHODS
The Enroll-HD Care Improvement Committee
developed a 69-item survey instrument that captures
information on the populations served by HD-centers,
characteristics of health care delivery and organiza-
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tion of centers. The survey instrument was developed
through an iterative process by the members of
the Care Improvement Committee, which consist of
experienced HD-clinicians, patients’ representatives
and researchers, and seven study sites were involved
in pilot testing of the instrument. In addition to ques-
tions with predefined categories, there was room for
free-text comments. Quantitative data were analyzed
using descriptive statistics, and free-text comments
were read to assist data interpretation. The survey
was distributed electronically in English using Sur-
vey Monkey™. A total of 231 principal investigators
in Enroll-HD and other Enroll-HD eligible sites were
invited by e-mail to respond to the survey between
June 2014 and November 2014. Several reminders
were sent to increase the response rate.
RESULTS
Response rates
Of 231 sites surveyed, 121 (52.2%) responded.
The response rates varied for individual items in the
survey and across countries (Table 1). The response
rate was 100% for Canada, New Zealand, Denmark
and Norway, 83.3% for Brazil, 80.0% for Portu-
gal, 78.6% for Italy, 76.5% for Germany, 60.0%
for Poland, 52.0% for the United States of Amer-
ica, 53.8% for the United Kingdom, and 50.0% for
France and the Netherlands. Response rates were less
than 50% for Argentina, Australia, Austria, Belgium,
Chile, Colombo, Czech Republic, Finland, Ireland,
Mexico, Peru, Russia and Spain.
Population served by HD Clinics
There was variability in size of population served
by each HD center in our sample. The majority
(61.1%) of centers serves a population of more than
1.5 million people, with a further 27.3% serving
500,000-1.5 million (Table 1). Only 11.5% of centers
served a population of less than 500.000. One-third
(29.3%) ran clinics in more than one geographical
location. Around half of patients (53.9%) across all
centers had less than 60 minutes estimated travelling
time to the center.
Frequency of clinical review offered
The number of individuals followed up by a clinic
on a regular basis varied across centers (Table 2).
One-fifth (18.5%) of centers cared for 1–49 patients,
Table 1
Characteristics of the population served
Survey item (number of respondents to the item) N (%)
Size of population served (N = 121)
≤500.000 14 (11.5)
500.001–1.500.000 33 (27.3)
1.500.001–3.000.000 23 (19.0)
>3.000.000 51 (42.2)
Clinic in more than one location (N = 121)
Yes 36 (29.7)
No 85 (70.3)
Groups of patients seen (N = 117)
People at risk 110 (94.0)∗
Pre-symptomatic gene carriers 109 (93.2)∗
Symptomatic (early and mid-stage) 116 (99.2)∗
Symptomatic (late stages) 108 (92.3)∗
Number of patients followed (N = 119)
1–49 22 (18.5)
50–99 35 (29.4)
100–199 36 (30.3)
>200 26 (21.8)
See patients outside their region (N = 121)
Yes 104 (86.0)
No 17 (14.0)
Reasons for out of region referrals (N = 102)
The nearest specialist center 65 (63.7)∗
Patient choice 72 (70.6)∗
Other reasons 25 (24.5)∗
Estimated travel time for patients (N = 102)
<30 min 5 (4.9)
30–60 min 50 (49.0)
61–120 min 37 (36.3)
>121 min 10 (9.8)
∗Several response alternatives allowed to the survey item.
29.4% followed 50–99, 30.3% followed 100–199,
and 21.8% cared for more than 200 patients. One-
third of centers (33.6%) offered specialist inpatients
beds for HD. The majority (86.0%) reported seeing
patients from outside their own geographical region,
and reasons listed for such referrals were patient’s
own choice (70.6%) and being the nearest specialist
center (63.7%). Among other reasons (24.5%) listed
were the center’s reputation, being a research cen-
ter and participating in clinical trials, and lack of
expertise elsewhere.
Mission statements
One-quarter (27.8%) of centers have a mission
statement. Some centers are located within larger
units with a mission statement, for example: “Our
mission is to improve the quality of life of persons
with movement disorders throughout the spectrum
of their condition by offering patient and family
centered services through an innovative multidisci-
plinary approach”. Some statements were brief and
general: “To provide the right care, at the right time,
210 J.C. Frich et al. / Health Care Delivery in Huntington’s Disease
Table 2
Characteristics of service delivery in HD-centers
Survey item (number of respondents to the item) N (%)
Consultation in a clinic for
HD patients only (N = 117)
Yes 50 (42.7)
No 67 (57.3)
Access to specialist HD inpatient beds (N = 110)
Yes 37 (33.6)
No 73 (66.4)
Where are patients seen? (N = 108)
Outpatient clinic 106 (98.2)∗
Inpatient ward 32 (29.6)∗
Other 8 (7.4)∗
Outreach visits in the community (N = 108)
Yes 52 (48.1)
No 56 (51.9)
Where outreach visits takes place (N = 50)
General practice/health center 14 (28.0)∗
Specialist practice 9 (18.0)∗
Patients’ homes 36 (72.0)∗
See patients in other hospitals/care facilities (N = 106)
Yes 51 (48.1)
No 55 (51.9)
Use of videoconferencing/telemedicine (N = 106)
Yes 25 (23.6)
No 81 (76.4)
With whom do you use videoconferencing
or telemedicine? (N = 24)
Patient consultations 11 (45.8)∗
Other clinicians 15 (62.5)∗
Other 6 (25.0)∗
Multidisciplinary case review meetings
for professionals (N = 110)
Yes 60 (54.5)
No 50 (45.5)
∗Several response alternatives allowed to the survey item.
in the right place”, and “To provide the best clinical
care to HD patients”. Others focus on being a multi-
disciplinary clinic: “ . . . to provide the best clinical
care and services for individuals affected with HD
and their families. This includes clinical and social
services, educational outreach and research opportu-
nities”. One group of centers referred to the HDSA
Center of Excellence guidelines, and had built their
mission statement according to these, for example:
“The HDSA Center of Excellence at [hospital] is
dedicated to serving the needs of those affected by
Huntington’s disease (HD). Our goals are (1) to max-
imize quality of life, (2) to provide education and
training opportunities about HD and (3) to conduct
research into the causes and consequences for HD
and into potential treatments”.
Organization of care delivery
Most centers (86.8%) offer consultations to those
at-risk and to presymptomatic gene carriers as well
as those with a clinical diagnosis of HD (Table 1).
Free text comments suggest that many centers are
embedded within larger clinics, such as a Department
of Neurology or Department of Medical Genetics,
and that it is commonplace to run HD-clinics on
certain days during the week. Almost half (48.1%)
of the centers offer outreach visits in the commu-
nity, and 72% of centers will sometimes see patients
in their own homes (Table 2). Half of the clinics
(48.1%) report offering outreach services such as
seeing patients in other hospitals and care facili-
ties, such as nursing homes, residential care facilities,
and psychiatric hospitals. Interestingly, videoconfer-
ences and telemedicine was used by almost a quarter
(23.6%) of clinics. Multidisciplinary case reviews
were arranged by a majority (54.5%) of centers.
Healthcare specialties, staff and services
in centers
Twenty-two different health professional special-
ties were represented at HD clinics (Table 3); in
addition to the specialties listed in the survey, a
number of centers listed additional specialists in
free-text comments, such as gastroenterologist, legal
advisor, dementia coordinator, and palliative care.
The specialists most frequently included in HD
clinics were neurologists (66.7%), neuropsycholo-
gists (57.3%), research nurses (52.1%), geneticists
(49.6%), genetic counsellor (48.7%), psychiatrist
(45.3%), social worker (43.6%), and specialist nurse
(41.9%). Centers offered a wide variety of services
such as clinical review, assessment and review of
medication, neurological examination, neuropsycho-
logical assessment, diagnostic and predictive testing,
genetic counseling and behavioral and crisis manage-
ment (Table 4).
Clinical routines and management
Frequency of follow-up varied according to dis-
ease stage (Table 5). Most patients at risk are seen
annually (43%) or as requested by the patient (40%).
Early stage patients are usually seen either every
sixth months (40%) or annually (39%). Mid stage
patients are seen more often with 28% being seen
three monthly, and 47% being seen six monthly. Late
stage patients are seen a little less frequently than mid
stage patients.
About half (53.7%) of the clinics offer new patients
between 46 min and 1 hour consultations; with a
further fifth (19.5%) offering longer appointments
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Table 3
Characteristics of the health care staff in HD-centers (N = 117)
Professionals and staff working for the center N (%)
Neurologist 78 (66.7)
Neuropsychologist 67 (57.3)
Research nurse 61 (52.1)
Geneticist 58 (49.6)
Genetic counselor 57 (48.7)
Research assistant 57 (48.7)
Psychiatrist 53 (45.3)
Social worker 51 (43.6)
Specialist nurse 49 (41.9)
Secretarial or support staff 47 (40.2)
Speech and language therapist 42 (35.9)
Physiotherapist 36 (30.8)
Psychologist 32 (27.4)
Dietitian 32 (27.4)
Occupational therapist 30 (25.6)
Family group representative/ 25 (21.4)
Huntington’s disease association advisor
Neuropsychiatrist 22 (18.8)
Nurse practitioner 22 (18.8)
Care coordinator 17 (14.5)
General practitioner, dentist, youth worker, other 25 (21.4)
Table 4
Content of service provision in HD-centers (N = 111)
Service provided N (%)
Clinical review, assessment and review 107 (96.4)
of medication
Neurological examination 107 (96.4)
Neuropsychological assessment 95 (85.6)
Diagnostic testing 95 (85.6)
Genetic counseling 89 (80.2)
Behavioral management 85 (76.6)
Predictive testing 84 (75.7)
Crisis management 81 (73.0)
Psychological support 75 (67.6)
Therapeutic counseling 72 (64.9)
Speech and language therapy 54 (48.7)
Physiotherapy 51 (46.0)
Benefit advice 50 (45.1)
Educational services/training 46 (41.4)
Occupational therapy 43 (38.7)
Peer support groups 34 (30.6)
Housing support 29 (26.1)
Respite care 16 (14.4)
Other (dental advice, therapy, nutrition advice, 15 (13.5)
support groups and advanced neuroimaging)
(Table 6). Time spent with the lead clinician for return
patients was reported never to be more than 60 min-
utes, and most consultations (70.7%) lasted between
16 and 45 minutes. Almost all clinics (94.1%) offer
appointments to caregivers. Clinics offer caregivers
to be seen together with the patient (94.8%), and a
majority of clinics also offer separate consultations
for caregivers (58.3%). In addition to scheduled vis-
its, more than half (55.0%) of the centers offered face
to face interaction with patients between clinic visits
(Table 5). Additional support was provided by nearly
all clinics by telephone (98.2%), and sometimes by e-
mail (68.5%) or through videoconferencing (10.8%).
About half of the centers (57.3%) formulated indi-
vidualized care management plans. Most centers
(70.4%) reported following published guidelines or
local pathways for HD.
DISCUSSION
This survey provides some insight into factors
underpinning HD service delivery around the world.
Our results suggest that the majority of centers serve
large populations. Half of the centers offer commu-
nity based care or domiciliary visits, and one-quarter
use videoconferencing and telemedicine. We also
found that most centers provide care in all stages of
HD, including to asymptomatic and at-risk individ-
uals, and that there seems to be consistent patterns
of the frequency of follow-up according to disease
stage.
Multidisciplinary care
The literature strongly promotes a multidisci-
plinary approach to HD [1, 14–17], and our study
suggests that the majority of HD centers surveyed
provides multidisciplinary care. More than half of
the clinics are staffed with a neurologist, neuropsy-
chologist, research nurse and/or a geneticist, but the
presence of other professional groups varies. Notably,
less than half the centers include a physiotherapist,
occupational, speech and language, or nutritional
therapist (dietitian). It may be that other services have
good access to these specialties and services in the
health care system. This variability in access to ser-
vices at different centers suggests that more research
should be conducted to understand how centers are
organized and how they interact with the rest of the
local health care system.
Research on health outcomes in HD
While there is research in support of multidisci-
plinary approaches to other chronic diseases, little is
known about how health care delivery models impact
on outcomes for patients and family members con-
fronting this genetic disorder of mid-adulthood. We
think our results will help in the design of future
studies of how care provision may be associated
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Table 5
Follow-up regimen in HD-centers for different categories of patients
None 3 months 6 months Annual Bi-annual Patient’s request
Patient category % % % % % %
At risk/presymptomatic (N = 97) 4 3 9 43 1 40
Early stage (N = 100) 1 13 40 39 1 6
Mid stage (N = 100) 0 28 47 19 0 6
Late stage (N = 94) 1 28 35 22 1 13
Table 6
Characteristics of patients’ consultations and caregivers’ follow-up
Survey item (number of respondents to the item) N (%)
Time spent with the lead clinician
for new patients (N = 41)
0–15 min 0 (0)
16–30 min 5 (12.2)
31–45 min 6 (14.6)
46–60 min 22 (53.7)
>60 min 8 (19.5)
Time spent with lead clinician
for returning patients (N = 41)
0–15 min 4 (9.8)
16–30 min 15 (36.6)
31–45 min 14 (34.2)
46–60 min 8 (19.5)
Caregivers seen in the clinic (N = 102)
Yes 96 (94.1)
No 6 (5.9)
Consultation services for caregivers (N = 96)
Together with patient 91 (94.8)
Separately at the same clinic 56 (58.3)
Separately at different location 9 (9.4)
Other 9 (9.4)
Face to face interactions between visits (N = 111)
Yes 61 (55.0)
No 50 (45.0)
If yes, where? (N = 61)
Outpatient clinic 50 (82.0)
Nursing homes 29 (47.5)
Inpatient ward/psychiatric hospital 25 (41)
Patients’ homes 24 (39.3)
Residential care facility 20 (32.8)
Non-face to face support (N = 111)
Telephone 109 (98.2)
Email 75 (68.5)
Videoconferencing 12 (10.8)
Formulate individualized care
management plans (N = 110)
Yes 63 (57.3)
No 47 (42.7)
Follow guideline or local care pathway (N = 108)
Yes 76 (70.4)
No 32 (29.6)
with favourable patient and family outcomes. The
variation in service delivery offers the opportunity
for the parent Enroll-HD study to elucidate whether
having such specialties integrated into the clinic is
associated with better outcomes in HD. Documenta-
tion of effects and outcomes has become important
as patients, families, clinicians advocate improving
funding of care and support systems. While this
study begins to approach this problem from the clin-
ical service perspective, there is a need understand
more about how structural and processual factors are
associated with good quality outcome measures. The
ultimate goal should be to develop models of care that
improve outcomes in HD.
Strengths and weaknesses of the study
The overall response rate in this study was 52.2%,
with variation in response rates across countries.
Non-responders could have introduced selection bias.
There may be regional differences in the degree
to which HD-care is centralized, and patients may
receive care outside of specialty HD clinics, or may
also lack access to professional care. As the centers
surveyed are those that are participating in or eligi-
ble for Enroll-HD, centers not involved in research
and small centers are not represented in our sam-
ple. Centers in our sample may be able to offer a
higher level of services compared with other centers,
partly as a result of funding from research. Still, the
study’s strength is that it presents data from a large
number and range of HD-centers that are involved
in research worldwide, and it is the first study to
map health care delivery practices in HD globally.
With these limitations in mind one may question to
what extent our findings are generalizable to HD-care
in general. Still we think our findings give valu-
able insights into variations and patterns of HD care
delivery.
CONCLUSION
Most centers in this study serve a large popula-
tion and use a multidisciplinary approach. The survey
gives insight into factors underpinning HD service
delivery globally. There is a need for more in-depth
studies of clinical practice to understand how ser-
vices are organized and how such features may be
associated with quality of care.
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